Company: ERAS
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0000950170-25-042682
Chunk: 20

Company: Erasca, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 1
Chunk 20
---
 which may induce antitumor activity mediated by the immune system, such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and/or complement-dependent cytotoxicity. We believe these design attributes can potentially enable our proprietary bispecific anti-EGFR antibodies to achieve meaningfully improved activity relative to currently approved anti-EGFR antibodies, such as cetuximab, panitumumab, and amivantamab, since those antibodies preferentially bind EGFR only in the inactive state and may not as strongly elicit antitumor immunological responses.

15

Our pipeline

We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry, consisting of modality-agnostic programs aligned with our three therapeutic strategies of: (1) targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; (2) targeting RAS directly; and (3) targeting escape routes that emerge in response to treatment. The table below summarizes our current pipeline. Other than with respect to ERAS-0015 in China, Hong Kong, and Macau, we have exclusive worldwide development and commercial rights for all of our programs.

Our pipeline also includes ERAS-801, a brain-penetrant EGFR inhibitor in development for patients with EGFR-altered GBM (for which we are concluding a Phase 1 trial and exploring further advancement, including via partnerships and investigator-sponsored trials), ERAS-007 ERK1/2 inhibitor, and ERAS-601 SHP2 inhibitor. ERAS-007 and ERAS-601 are being assessed in preclinical studies as potential combination partners with other programs in our pipeline for RAS/MAPK pathway inhibition. Via Erasca Ventures, we made an equity investment in Affini-T, which is developing TCR T-cell therapies against KRAS G12V, KRAS G12D, and KRAS G12C.

Naporafenib: our pan-RAF inhibitor

Our lead product candidate is naporafenib, for which we initiated a pivotal Phase 3 trial in the first half of 2024 for patients with NRASm melanoma. Naporafenib is a pan-RAF inhibitor with first-in-class and best-in-class potential for patients with NRASm melanoma and other RAS/MAPK pathway-driven tumors. In-licensed from Novartis, naporafenib has been dosed in over 600 patients to date, whereby safety, tolerability, and acceptable